Вы находитесь на странице: 1из 64

Supplementary tables: Third quarter 2008 – Net sales of top 20 pharmaceutical products (una

Company Drug (Brand Name) Drug (Generic Name)

Novertis AG
Cardiovascular & Metabolism
Diovan valsartan, nateglinide
Lotrel amlodipine, benazepril
Exforge
Tekturna/Rasilez aliskiren
Other
Total strategic franchise products
Mature products (including Lescol)
Total Cardiovascular & Metabolism products
Oncology & Hematology
Gleevec/Glivec
Zometa
Sandostatin
Femara
Exjade
Other
Total Oncology & Hematology products
Neuroscience & Ophthalmics
Lucentis
Exelon/Exelon Patch
Comtan/Stalevo
Tegretol
Ritalin/Focalin
Trileptal
Other
Total strategic franchise products
Mature products
Total Neuroscience & Ophthalmics products
Respiratory
Foradil
Tobramycin
Xolair omalizumab
Other
Total strategic franchise products
Mature products
Total Respiratory products
Immunology & Infectious Diseases (IID)
Neoral/Sandimmun
Myfortic
Aclasta/Reclast
Elidel
Other
Total strategic franchise products
Mature products
Total IID products
Additional mature products
Voltaren (Excluding OTC)
Enablex/Emselex
Prexige
Zelnorm/Zelmac
Other
Total additional mature products
Mature products
Total additional mature products

Ophthalmics, Dermatology,Gastrointestinal and Urology (ODGU)


Lucentis
Enablex/Emselex
Elidel
Zelnorm/Zelmac
Other
Total strategic franchise products
Mature products (including Lamisil)
Total ODGU products

Total strategic franchise products


Total mature products
Total Division net sales
pharmaceutical products (unaudited)
Geographic Revenue
Indication Segment (currency/units)
1Q03

Prevention of new-onset type 2 diabetes,


High-risk hypertension
High blood pressure
Type 2 diabetes

Allergic asthma

Post-menopausal osteoporosis
2Q03 3Q03 4Q03 1Q04 2Q04 3Q04 4Q04 1Q05
2Q05 3Q05 4Q05 1Q06 2Q06 3Q06 4Q06 1Q07
2Q07 3Q07 4Q07 1Q08 2Q08 3Q08 4Q08 1Q09

5012 1369 1509 1443


748 95 100 101
103 72 101 115
40 28 30 40
8 6 8 12
5911 1570 1748 1711
1494 377 398 361
7405 1947 2146 2072

3050 888 942 950


1297 331 346 360
1027 269 289 294
937 270 291 289
357 109 129 148
283 81 98 96
6951 1948 2095 2137

195 242 221


632 188 203 215
420 114 131 131
413 114 131 109
375 106 114 100
692 90 83 86
382 196 229 188
2914 1003 1133 1050
431 105 106 102
3345 1108 1239 1152

362 105 104 97


273 73 72 74
140 39 56 61
87 27 25 25
862 244 257 257
97 28 21 17
959 272 278 274

944 245 258 235


78
39 64 66
42 41 35
448 144 165 93
1392 470 528 507
247 198 294 245
1639 668 822 752
202 216 206
46 49 54
91 10 13 (2)
2 3 3
41 61 67 61
132 321 348 322
1442
1574 321 348 322

393
179
176
88
605
1441 0 0 0
711
2152 0 0 0

19603 5235 5761 5662


4422 1029 1167 1047
24025 6264 6928 6709
2Q09 3Q09 4Q09
Company Drug (Brand Name)
1Q03 2Q03
3/31/2003 6/30/2003
Novertis AG
Net sales

Pharmaceuticals
sandoz
OTC
Animal health
Medical nutrition
Infant&baby
CIBA vision
Vaccines and Diagnostics
Sandoz
Consumer Health continuing operations
Net sales from continuing operations
Consumer Health discontinuing operations
Total

Net sales of top 20 pharmaceutical products

Diovan/Co–Diovan
US
Rest of world
Total

Gleevec/Glivec
US
Rest of world
Total

Lamisil (group)
US
Rest of world
Total

Zometa
US
Rest of world
Total

Sandostatin
US
Rest of world
Total

Femara
US
Rest of world
Total

Neoral/Sandimmun
US
Rest of world
Total

Lucentis
US
Rest of world
Total

Voltaren (Excl. OTC)


US
Rest of world
Total

Exelon/Exelon Patch
US
Rest of world
Total

Lescol
US
Rest of world
Total

Top ten products total


US
Rest of world
Total

Exjade
US
Rest of world
Total

Elidel
US
Rest of world
Total

Comtan/Stalevo
US
Rest of world
Total

Visudyne
US
Rest of world
Total
Tegretol
US
Rest of world
Total

Ritalin/Focalin
US
Rest of world
Total

Foradil
US
Rest of world
Total

Lotrel
US
Rest of world
Total

Exforge
US
Rest of world
Total

Trileptal
US
Rest of world
Total

Tobramycin
US
Rest of world
Total

Miacalcic
US
Rest of world
Total

Myfortic
US
Rest of world
Total

Leponex/Clozaril
US
Rest of world
Total

Famvir
US
Rest of world
Total

Zelnorm/Zelmac
US
Rest of world
Total

Cibacen/Lotensin/Cibadrex
US
Rest of world
Total

HRT range
US
Rest of world
Total

Top 20 products total


US
Rest of world
Total

Rest of portfolio
US
Rest of world
Total

Total Division sales


US
Rest of world
Total

Pharmaceutical net sales by therapeutic area

Cardiovascular & Metabolism


Diovan
Lotrel
Exforge
Tekturna/Rasilez
Lescol
Other
Total strategic franchise products
Mature products (including Lescol)
Total Cardiovascular & Metabolism products

Oncology & Hematology


Gleevec/Glivec
Zometa
Sandostatin
Femara
Exjade
Other
Total Oncology & Hematology products

Neuroscience & Ophthalmics


Lucentis
Exelon/Exelon Patch
Comtan/Stalevo
Tegretol
Ritalin/Focalin
Trileptal
Other
Total strategic franchise products
Mature products
Total Neuroscience & Ophthalmics products

Respiratory & Dermatology


Lamisil (group)
Foradil
Elidel
Xolair
Other
Total strategic franchise products
Mature products
Total Respiratory & Dermatology products

Respiratory
Foradil
Tobramycin
Xolair
Other
Total strategic franchise products
Mature products
Total Respiratory products

Immunology & Infectious Diseases (IID), transplantation


Neoral/Sandimmun
Myfortic
Aclasta/Reclast
Elidel
Other
Total strategic franchise products
Mature products
Total IID products
Arthritis/Bone/Gastrointestinal/ Urinary (ABGU)
Zelnorm/Zelmac
Prexige
Other
Total strategic franchise products
Mature products
Total ABGU products

Additional mature products


Voltaren (Excluding OTC)
Enablex/Emselex
Prexige
Zelnorm/Zelmac
Other
Total additional mature products

Ophthalmics, Dermatology,Gastrointestinal and Urology (ODGU)


Lucentis
Enablex/Emselex
Elidel
Zelnorm/Zelmac
Visudyne
Other
Total strategic franchise products
Mature products (including Lamisil)
Total ODGU products

Total strategic franchise products


Total mature products
Prior-years' US sales rebate accounting adjustment
Total Division net sales

Net sales by region

Pharmaceuticals
US
Rest of world
Total

Sandoz
US
Rest of world
Total

OTC
US
Rest of world
Total

ANIMAL HEALTH
US
Rest of world
Total

Medical nutrition
US
Rest of world
Total

Infant and baby


US
Rest of world
Total

CIBA vision
US
Rest of world
Total

Vaccines and Diagnostics


US
Rest of world
Total

Sandoz
US
Rest of world
Total

Consumer Health continuing operations


US
Rest of world
Total

Group continuing operations


US
Rest of world
Total

Net sales by region


US
Europe
Rest of world
Total
ASSOCIATES BY REGION AND DIVISION
Pharmaceuticals
US
Canada and Latin america
Europe
Asia/Africa/Australia
Total

Vaccines and Diagnostics


US
Canada and Latin america
Europe
Asia/Africa/Australia
Total

Sandoz
US
Canada and Latin america
Europe
Asia/Africa/Australia
Total

Consumer Health
US
Canada and Latin america
Europe
Asia/Africa/Australia
Total

corporate
US
Canada and Latin america
Europe
Asia/Africa/Australia
Total

Total
US
Canada and Latin america
Europe
Asia/Africa/Australia
Total

Net sales By country


Switzerland
USA
Germany
Japan
France
UK
Australia
Slovenia
Singapore
Other
Total group
Less dicontinued operations
Total continuing operations
3Q03 4Q03 1Q04 2Q04 3Q04 4Q04 1Q05 2Q05
9/30/2003 12/31/2003 3/31/2004 6/30/2004 9/30/2004 12/31/2004 3/31/2005 6/30/2005

4,379 4,310 4,572 4,646 4,969 4,789 5,132


768 719 737 722 867
499 498 467 478 532
180 168 185 194 209
208 258 289 289 285
348 349 367 371 354
348 337 356 357 362

803 832
2,351 2,329 2,401 2,411 2,609 1,749 1,835
6,730 6,639 6,973 7,057 7,578 7,341 7,799

6,730 6,639 6,973 7,057 7,578 7,341 7,799

368 335 323 351 314 358 374


400 398 433 437 502 487 538
668 733 756 788 816 845 912

82 75 100 93 100 117 118


251 276 306 318 366 379 419
333 351 406 411 466 496 537

111 104 141 158 125 115 140


158 114 158 186 176 134 175
269 218 299 344 301 249 315

148 146 166 151 167 167 178


92 105 109 111 123 129 134
240 251 275 262 290 396 312

86 88 84 95 107 93 99
98 113 110 112 118 128 133
184 201 194 207 225 221 232

29 40 46 51 54 63
49 52 55 64 64 73
78 92 101 115 118 136

55 46 48 41 45 38 37
221 205 203 199 224 188 207
276 251 251 240 269 226 244

0 2 3 2 2 2 1
163 144 150 157 178 159 184
163 146 153 159 180 161 185

43 49 40 46 44 48 37
53 57 60 61 65 69 73
96 106 100 107 109 117 110

95 62 68 77 77 48 69
117 111 116 118 129 124 136
212 173 184 195 206 172 205

58 63 74 68 74 81 37
12 17 18 16 19 25 21
70 80 92 84 93 106 58

30 31
32 36
62 67

47 45 53 56 55 51 50
49 56 56 58 69 73 79
96 101 109 114 124 124 129
38 25 24 26 28 25 27
75 68 68 72 85 72 74
113 93 92 98 113 97 101

2 2 4 3 4 5 3
77 77 72 76 83 87 79
79 79 76 79 87 92 82

184 215 234 212 259 231 278


0 0 0 0 0
184 215 234 212 259 231 278

87 96 84 105 106 115 103


26 29 30 32 36 37 38
113 125 114 137 142 152 141

53 51 68 63 54 58 58
41 35 35 33 38 34 36
94 86 103 96 92 92 94

22 15 20 19 18 14 15
61 63 58 59 56 47 45
83 78 78 78 74 61 60
35 42 43 39
25 23 23 25
60 65 66 64

58 63 71 57 68 86
10 13 12 15 12 16
68 76 83 72 80 102

70 55
35 33
105 88

30
26
56

1,514 1,561 1,679 1,726 1,726 1,718 1,804


1,980 1,960 2,070 2,135 2,371 2,280 2,496
3,494 3,521 3,749 3,861 4,097 3,998 4,300

197 172 167 169 168 166 209


688 617 656 616 704 687 623
885 789 823 785 872 853 832

1,733 1,846 1,895 1,894 1,884 2,013


2,577 2,726 2,751 3,075 2,967 3,119
4,310 4,572 4,646 4,969 4,851 5,132

845 912
231 278

172 205
31 35
1,279 1,430
188 153
1,467 1,583

496 537
296 312
221 232
118 136

71 74
1,202 1,291

117 110

97 101

152 141
172 196
538 548
129 116
667 664

249 315
106 82
92 58

14 13
461 468
49 35
510 503

226 244

28 32
254 276
80 102

72 74
152 176
379 418
531 594

rology (ODGU)

124 129
96 92
220 221

4,106 4,410
745 722
-62
4,789 5,132

1,733 1,846 1,895 1,894 1,822 2,013


2,577 2,726 2,751 3,075 2,967 3,119
4,310 4,572 4,646 4,969 4,789 5,132

226 264 219 272


493 473 503 595
719 737 722 867

129 120 129 143


369 347 349 389
498 467 478 532

59 69 89 91
109 116 105 118
168 185 194 209

89 104 117 105


169 185 172 180
258 289 289 285

289 300 305 290


60 67 66 64
349 367 371 354

110 124 127 120


227 232 230 242
337 356 357 362

251 259
552 573
803 832

902 981 986 1,021 744 797


1,427 1,420 1,425 1,588 1,005 1,038
2,329 2,401 2,411 2,609 1,749 1,835

2,635 2,827 2,881 2,915 2,817 3,069


4,004 4,146 4,176 4,663 4,524 4,730
6,639 6,973 7,057 7,578 7,341 7,799

2,827 2,881 2,915 3,069


2,522 2,506 2,734 2,812
1,624 1,670 1,929 1,918
6,973 7,057 7,578 7,799
3Q05 4Q05 1Q06 2Q06 3Q06 4Q06 1Q07 2Q07
9/30/2005 12/31/2005 3/31/2006 6/30/2006 9/30/2006 12/31/2006 3/31/2007 6/30/2007

5,093 5,248 5,052 5,699 5,776 6,049 5,923 6,065

127 374 455 231 251


1,486 1,573 1,431 1,450 1,425 1,653 1,696 1,719
1,836 1,836 1,818 1,906 1,909 1,644 1,721 1,365
8,415 8,657 8,301 9,182 9,484 9,801 9,571 9,400
252 248 722
8,415 8,657 8,301 9,182 9,484 10,053 9,819 10,122

402 417 412 448 493 505 523 546


523 577 527 596 595 647 628 693
925 994 939 1,044 1,088 1,152 1,151 1,239

136 153 132 157 168 173 156 177


411 437 427 483 485 529 518 570
547 590 559 640 653 702 674 747

156 127 119 172 156 127 132 130


162 124 81 111 113 99 75 95
318 251 200 283 269 226 207 225

172 187 185 166 171 174 159 160


130 127 134 142 146 165 155 162
302 314 319 308 317 339 314 322

89 95 88 85 95 99 95 103
130 129 128 138 136 146 143 150
219 224 216 223 231 245 238 253

58 67 72 84 90 92 96 103
78 79 80 90 99 112 112 128
136 146 152 174 189 204 208 231

36 39 33 30 31 31 30 26
206 202 181 205 198 209 194 207
242 241 214 235 229 240 224 233

2 0 3 3 0 2 2 0
172 169 157 174 175 176 169 185
174 169 160 177 175 178 171 185

42 45 42 42 54 49 50 48
77 76 74 86 89 89 96 103
119 121 116 128 143 138 146 151

70 70 62 58 75 61 56 51
124 126 116 120 115 118 115 117
194 196 178 178 190 179 171 168

46
46
92

38 36
15 17
53 53

36 36 36 37 43 41 42 45
38 39 41 44 46 51 52 61
74 75 77 81 89 92 94 106

51 31 31 18 11 10
73 76 76 77 64 67
124 107 107 95 75 77
29 28 28 31 29 32 32 31
70 68 66 67 66 72 67 74
99 96 94 98 95 104 99 105

62 60 63 79 85 72
16 17 16 17 16 20
78 77 79 96 101 92

3 3 4 3 3 4 6 4
74 78 83 74 72 88 82 88
77 81 87 77 75 92 88 92

269 297 295 348 355 354 353 241


0
269 297 295 348 355 354 353 241

125 119 126 142 136 145 150 150


40 38 40 44 44 44 47 49
145 157 166 186 180 189 197 199

44 41
25 24
69 65

62 51 52 53 47 47 41 37
32 34 36 38 31 35 33 32
94 85 88 91 78 82 74 69
41 41 36 40 44 46 47 48
27 25 25 27 25 25 23 24
68 66 61 67 69 71 70 72

97 106 93 136 127 132 90


16 17 16 18 18 21 15
113 123 109 154 145 153 105

1,914 1,948 1,911 2,113 2,191 2,203 2,189 2,059


2,398 2,438 2,304 2,551 2,533 2,710 2,565 2,828
4,312 4,386 4,215 4,664 4,724 4,913 4,754 4,887

180 208 183 303 250 318 274 222


601 654 654 732 802 818 895 956
781 862 837 1,035 1,052 1,136 1,169 1,178

2,094 2,156 2,094 2,416 2,441 2,521 2,463 2,281


2,999 3,092 2,958 3,283 3,335 3,528 3,460 3,784
5,093 5,248 5,052 5,699 5,776 6,049 5,923 6,065

925 994 939 1,044 1,088 1,152 1,151 1,239


269 297 295 348 355 354 353 241

194 196 178 178 190 179


23 39 41 41 43 47 16 24
1,411 1,526 1,453 1,611 1,676 1,732 1,520 1,504
166 158 161 160 159 168 377 372
1,577 1,684 1,614 1,771 1,835 1,900 1,897 1,876

547 590 559 640 653 702 674 747


302 314 319 308 317 339 314 322
219 224 216 223 231 245 238 253
136 146 152 174 189 204 208 231
31 43 50 65 92
54 71 82 84 74 74 69 69
1,258 1,345 1,328 1,460 1,507 1,614 1,568 1,741

119 121 116 128 143 138 146 151


94 106
99 96 94 98 95 104 99 105
101 92
165 157 166 186 180 189 197 199
186 204 209 243 270 298 109 106
569 578 585 655 688 729 746 759
131 100 108 114 108 110 103 107
700 678 693 769 796 839 849 866

318 251 200 283 269 226


77 81 87 77 75 92
53 53 48 43 41 47
37 26 35
15 16 22 60 80 88
463 401 357 500 491 488
24 34 33 33 25 32
467 435 390 533 516 520

88 92
69 65
34 30
20 20
211 207
29 23
240 230

242 241 214 235 229 240 224 233

36 43 66 82 91 91 92 110
278 284 280 317 320 331 316 343
56 68 69 73 75 82
336 385 389 404 391 425
113 123 109 154 145 153
18 21 31
86 101 26 36 45 39 2 3
199 224 135 190 190 210 23 34
390 409 367 391 378 390 344 358
589 633 502 581 568 600 367 392

72
38 43
47 47
105 -14
124 107 107 95 75 77 61
80 82 82 105 90 95 125 161
204 189 189 200 165 172 376 309
235 253
611 562

4,382 4,547 4,327 4,933 5,037 5,276 4,760 4,870


711 701 725 766 739 773 1,163 1,195

5,093 5,248 5,052 5,699 5,776 6,049 5,923 6,065

2,094 2,156 2,094 2,416 2,441 2,521 2,463 2,281


2,999 3,092 2,958 3,283 3,335 3,528 3,460 3,784
5,093 5,248 5,052 5,699 5,776 6,049 5,923 6,065
46 186 230 72 74
81 188 225 159 177
127 374 455 231 251

314 458 371 378 377 422 474 479


1,172 1,115 1,060 1,072 1,048 1,231 1,222 1,240
1,486 1,573 1,431 1,450 1,425 1,653 1,696 1,719

820 859 872 889 881 874 891 908


1,016 977 946 1,017 1,028 1,022 1,078 1,179
1,836 1,836 1,818 1,906 1,909 1,896 1,969 2,087

3,228 3,473 3,337 3,729 3,885 4,047 3,900 3,742


5,187 5,184 4,964 5,453 5,599 6,006 5,919 6,380
8,415 8,657 8,301 9,182 9,484 10,053 9,819 10,122

3,228 3,473 3,337 3,729 3,885 4,047 3,900 3,742


3,208 3,132 3,086 3,318 3,482 3,705 3,808 4,010
1,979 2,052 1,878 2,135 2,117 2,301 2,111 2,370
8,415 8,657 8,301 9,183 9,484 10,053 9,819 10,122
3Q07 4Q07 1Q08 2Q08 3Q08 4Q08
9/30/2007 12/31/2007 3/31/2008 6/30/2008 9/30/2008 12/31/2008

5,885 6,152 6,264 6,928 6,709

572 398 280 322 666


1,783 1,971 1,906 1,948 1,899
1,373 1,410 1,459 1,528 1,473
9,613 9,931 9,909 10,726 10,747

564 561 570 613 612


703 794 799 896 831
1,267 1,355 1,369 1,509 1,443

180 201 206 216 232


603 645 682 726 718
783 846 888 942 950

7 -3
90 69
97 66

162 168 153 160 179


156 175 178 186 181
318 343 331 346 360

102 109 100 105 113


156 169 169 184 181
258 278 269 289 294

105 107 116 119 125


135 151 154 172 164
240 258 270 291 289

26 26 27 28 23
217 218 218 230 212
243 244 245 258 235

122 170 195 242 221


122 170 195 242 221

5 2 2 1 1
191 193 200 215 205
196 195 202 216 206

59 55 59 65 77
105 116 129 138 138
164 171 188 203 215

51 49 36 42 38
112 114 120 139 121
163 163 156 181 159

1,269 1,349 1,400


2,844 3,128 2,972
4,113 4,477 4,372

47 43 43 53 55
51 59 66 76 93
98 102 109 129 148

44 47 45 51 52
59 70 69 80 79
103 117 114 131 131
31 29 30 53 31
69 80 84 78 78
100 109 114 131 109

59 83 85 87 77
19 21 21 27 23
78 104 106 114 100

7 4 4 4 3
80 91 101 100 94
87 95 105 104 97

66 88 95 100 101

66 88 95 100 101

26 36 44
46 65 71
72 101 115

152 48 40 30 35
46 50 50 53 51
198 98 90 83 86

46 46 45 48
26 27 27 26
72 73 72 74

36 33
32 37
68 70

21 24 25
43 53 53
64 77 78
35
24
59

1,738 1,696 1,704 1,832 1,871


2,970 3,248 3,351 3,687 3,540
4,708 4,944 5,055 5,519 5,411

279 291 281 386 332


898 917 928 1,023 966
1,177 1,208 1,209 1,409 1,298

2,017 1,987 1,985 2,218 2,203


3,868 4,165 4,279 4,710 4,506
5,885 6,152 6,264 6,928 6,709

1,267 1,355 1,369 1,509 1,443


66 88 95 100 101
25 51 72 101 115
9 20 28 30 40

2 4 6 8 12
1,369 1,517 1,570 1,748 1,711
369 376 377 398 361
1,738 1,894 1,947 2,146 2,072

783 846 888 942 950


318 343 331 346 360
258 278 269 291 294
240 258 270 289 289
98 102 109 129 148
68 77 81 98 96
1,765 1,904 1,948 2,095 2,137

195 242 221


164 171 188 203 215
103 117 114 131 131
100 109 114 131 109
78 104 106 114 100
198 98 90 83 86
104 63 196 229 188
747 662 1,003 1,133 1,050
105 116 105 106 102
852 778 1,108 1,239 1,152

87 95 105 104 97
67 72 73 72 74
36 40 39 56 61
20 27 27 25 25
210 234 244 257 257
18 27 28 21 17
228 261 272 278 274

243 244 245 258 235


78
39 64 66
42 41 35
119 127 144 165 93
362 371 470 528 507
70 20 198 294 245
432 391 668 822 752
29 10
6 30
35 40
366 374
401 414

202 216 206


46 49 54
10 13 -2
2 3 3
61 67 61
321 348 322

122 170
47 51
39 43
-8 5

142 145
342 414
127 96
469 510

4,830 5,143 5,235 5,761 5,662


1,055 1,009 1,029 1,167 1,047

5,885 6,152 6,264 6,928 6,709

2,017 1,987 1,985 2,218 2,203


3,868 4,165 4,279 4,710 4,506
5,885 6,152 6,264 6,928 6,709
302 154 79 145 360
270 244 201 177 306
572 398 280 322 666

504 502 468 430 428


1,279 1,469 1,438 1,518 1,471
1,783 1,971 1,906 1,948 1,899

700 430 419 428 433


988 980 1,040 1,100 1,040
1,688 1,410 1,459 1,528 1,473

3,523 3,073 2,951 3,221 3,424


6,405 6,858 6,958 7,505 7,323
9,928 9,931 9,909 10,726 10,747

3,523 3,073 2,951 3,221 3,424


3,994 4,295 4,498 4,747 4,632
2,411 2,563 2,460 2,758 2,691
9,928 9,931 9,909 10,726 10,747
ANNUALS
2003 2004 2005 2006 2007
Pharmaceuticals
US 6 406 6 761 –5 –5 32
Rest of world 13 495 11 112 21
Total 19 901 17 873 11 4 100
Vaccines and Diagnostics
US 584 448 30 33 46 43
Rest of world 684 606 13 2 54
Total 1 268 1 54 20 15 100
Sandoz
US 1 327 1 457 –9 –10 23
Rest of world 4 426 3 741 18
Total 5 753 5 198 11 1 100
Consumer Health
continuing operations
US 1 280 1 335 –4 –4 29
Rest of world 3 180 2 681 19
Total 4 460 4 16 11 4 100
Group continuing operations
US 9 597 10 1 –4 –4 31
Rest of world 21 785 18 140 20
Total 31 382 28 141 12 4 100
38
9 68 62
100

57
100

28
6 77 72
100

33
8 71 67
100

36
8 69 64
100
Company Drug (Brand Name)
1Q03 2Q03
3Q03 4Q03 1Q04 2Q04 3Q04 4Q04 1Q05 2Q05
3Q05 4Q05 1Q06 2Q06 3Q06 4Q06 1Q07 2Q07
3Q07 4Q07 1Q08 2Q08 3Q08 4Q08 1Q09 2Q09 3Q09
4Q09

Вам также может понравиться